Rolf Arno Stahel
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Occupational and environmental lung diseases 79
- Lung Cancer Treatments and Mutations 73
- Lung Cancer Diagnosis and Treatment 36
- Oncology 117
- Lung Cancer Research Studies 43
- Co-authors
- Walter Weder (75 shared papers)Uwe Zangemeister‐Wittke (28 shared papers)Emanuela Felley‐Bosco (34 shared papers)Annemarie Ziegler (10 shared papers)Isabelle Opitz (39 shared papers)Enriqueta Felip (17 shared papers)Ana Paula Simões‐Wüst (10 shared papers)Solange Peters (35 shared papers)
- Journals
- Lung Cancer (61 papers)Annals of Oncology (61 papers)International Journal of Cancer (22 papers)Journal of Thoracic Oncology (20 papers)Journal of Clinical Oncology (13 papers)
- Partner nations
- SwitzerlandSpainUnited States
In The Last Decade
Rolf Arno Stahel
364 papers receiving 22.1k citations
Rolf Arno Stahel's Hit Papers
Peers
Comparison fields: 5 of 157
- Pulmonary and Respiratory Medicine 9.4k
- Oncology 7.8k
- Pathology and Forensic Medicine 3.2k
- Cancer Research 2.5k
- Genetics 1.2k
Countries citing papers authored by Rolf Arno Stahel
This map shows the geographic impact of Rolf Arno Stahel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Arno Stahel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Arno Stahel more than expected).
Fields of papers citing papers by Rolf Arno Stahel
This network shows the impact of papers produced by Rolf Arno Stahel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Arno Stahel. The network helps show where Rolf Arno Stahel may publish in the future.
Co-authors
The 25 scholars most cited alongside Rolf Arno Stahel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 368 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Hit paper breakdown → | 2006 | 1705 |
| 2 | DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy Hit paper breakdown → | 2006 | 1439 |
| 3 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Hit paper breakdown → | 2011 | 653 |
| 4 | Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Hit paper breakdown → | 2022 | 531 |
| 5 | Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma Hit paper breakdown → | 2009 | 476 |
| 6 | A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. | 2000 | 441 |
| 7 | 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 414 |
| 8 | EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours Hit paper breakdown → | 2021 | 405 |
| 9 | 2018 | 401 | |
| 10 | 2019 | 387 | |
| 11 | 2003 | 357 | |
| 12 | 2015 | 309 | |
| 13 | 2015 | 298 | |
| 14 | 1997 | 292 | |
| 15 | 2007 | 253 | |
| 16 | 2014 | 248 | |
| 17 | 2010 | 243 | |
| 18 | 2004 | 238 | |
| 19 | 2004 | 232 | |
| 20 | 2003 | 226 |
About Rolf Arno Stahel
Rolf Arno Stahel is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Immunology, having authored 368 papers that have together received 22.8k indexed citations. Recurring topics across this work include Occupational and environmental lung diseases (79 papers), Lung Cancer Treatments and Mutations (73 papers), Lung Cancer Research Studies (43 papers), Lung Cancer Diagnosis and Treatment (36 papers), Monoclonal and Polyclonal Antibodies Research (24 papers), Glycosylation and Glycoproteins Research (21 papers), Lymphoma Diagnosis and Treatment (20 papers) and Cancer Genomics and Diagnostics (20 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (9.4k citations), Oncology (7.8k citations), Pathology and Forensic Medicine (3.2k citations), Cancer Research (2.5k citations) and Genetics (1.2k citations). Rolf Arno Stahel has collaborated with scholars based in Switzerland, Spain and United States. Frequent co-authors include Walter Weder, Uwe Zangemeister‐Wittke, Emanuela Felley‐Bosco, Annemarie Ziegler, Isabelle Opitz, Enriqueta Felip, Ana Paula Simões‐Wüst, Solange Peters, Martin Filipits and Robert Pirker. Their work appears in journals such as Lung Cancer, Annals of Oncology, International Journal of Cancer, Journal of Thoracic Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.